Glioma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Glioma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month1 study across 1 company, in the next 180 days.
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NTHI | Neonc Technologies, Inc. | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain TumorsNCT06357377Nature and severity of adverse events | Phase 1 | Not yet recruiting | Oct 2026 | ≤ 72 d | 2026-01-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Glioma
most recently updated first58 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: PF-07799544, PF-07799933 | Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer) | 124 | 2022-11-30 | 2027-08-02 | in 347 d | 2026-08-14 |
| BDTX | Black Diamond Therapeutics, Inc. | $118M | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIINCT07326566Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) | Phase 2 | Recruiting | Drug: silevertinib in combination with temozolomide, temozolomide (TMZ) | Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer | 162 | 2026-05-05 | Nov 2028 | ≤ 833 d | 2026-08-13 |
| RIGL | Rigel Pharmaceuticals | $815M | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesNCT07486713Area Under the Plasma Concentration-Time Curve (AUC) of Probe Drugs | Phase 4 | Recruiting | Drug: Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies | 16 | 2026-02-23 | 2027-04-30 | in 253 d | 2026-08-11 |
| NUVB | Nuvation Bio Inc. | $2.4B | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseNCT07703436Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR) | Phase 2 | Not yet recruiting | Drug: Safusidenib | Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma, Oligodendroglioma, Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted, Astrocytoma IDH Mutant Grade 3, Astrocytoma IDH Mutant Grade 2 | 40 | Mar 2027 | Sep 2030 | ≤ 1,502 d | 2026-08-11 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2) | Phase 1 | Recruiting | Drug: PF-07799933, binimetinib, midazolam, fluorouracil, leucovorin, oxaliplatin · Biological: cetuximab | Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1) | 267 | 2022-07-05 | 2028-04-23 | in 612 d | 2026-07-31 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of DS-1001b in Patients With Gene IDH1-Mutated GliomasNCT03030066Percentage of participants with dose limiting toxicities | Phase 1 | Completed | Drug: DS-1001b | Glioma | 47 | 2017-01-19 | 2021-01-31actual | — | 2026-07-28 |
| LLY | Eli Lilly and Company | $1.15T | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsNCT04521686Recommended Phase 2 Dose (RP2D) | Phase 1 | Active, not recruiting | Drug: LY3410738, Gemcitabine, Cisplatin, Durvalumab | Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor | 200 | 2020-10-01 | 2023-07-17actual | — | 2026-07-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyNCT06413706Event Free Survival as Determined by Blinded Independent Review Committee | Phase 2 | Active, not recruiting | Drug: Abemaciclib, Temozolomide | Glioma | 45 | 2024-10-25 | Feb 2027 | ≤ 192 d | 2026-07-17 |
| NUVB | Nuvation Bio Inc. | $2.4B | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant GliomaNCT07712757Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 | Phase 3 | Not yet recruiting | Drug: Safusidenib, Placebo | Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2, Oligodendroglioma, Oligodendroglioma IDH-mutant and 1p/19q-codeleted, IDH-mutant Gliomas | 140 | Mar 2027 | May 2029 | ≤ 1,015 d | 2026-07-17 |
| NUVB | Nuvation Bio Inc. | $2.4B | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)NCT05303519Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) | Phase 3 | Recruiting | Drug: safusidenib, Placebo | Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2, Oligodendroglioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted | 365 | 2023-06-05 | 2028-12-01 | in 834 d | 2026-07-01 |
| RIGL | Rigel Pharmaceuticals | $815M | Study of Olutasidenib and Temozolomide in HGGNCT06161974Establish the RP2D of Olutasidenib and Temozolomide (Feasibility cohort) | Phase 2 | Recruiting | Drug: Olutasidenib + TMZ | High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma | 60 | 2025-02-01 | Jun 2029 | ≤ 1,045 d | 2026-06-12 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)NCT05580562Overall survival (OS) | Phase 3 | Recruiting | Drug: Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo · Other: Placebo | H3 K27M, Glioma | 510 | 2023-01-23 | Jun 2028 | ≤ 680 d | 2026-04-16 |
| TNGX | Tango Therapeutics, Inc. | $4.3B | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossNCT06810544Phase 1 Maximum Tolerated Dose | Phase 1/2 | Recruiting | Drug: TNG456, abemaciclib | Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor | 191 | 2025-03-24 | 2027-03-31 | in 223 d | 2026-04-13 |
| ACTU | Actuate Therapeutics Inc. | $25M | 9-ING-41 in Patients With Advanced CancersNCT03678883Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 | Phase 2 | Active, not recruiting | Drug: 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan | Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma | 350 | 2019-01-04 | Jun 2026 | — | 2026-04-03 |
| CLRB | Cellectar Biosciences, Inc. | $24M | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGNCT05610891Safety Evaluation of CLR 131 | Phase 1 | Active, not recruiting | Drug: CLR 131 | High-Grade Glioma | 50 | 2023-10-01 | May 2026 | — | 2026-03-18 |
| NTHI | Neonc Technologies, Inc. | $143M | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain TumorsNCT06357377Nature and severity of adverse events | Phase 1 | Not yet recruiting | Drug: NEO100 | Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma | 12 | Jan 2026 | Oct 2026 | ≤ 72 d | 2026-01-14 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsNCT04541082Maximum Tolerated Dose (MTD) of single-agent, oral ONC206 | Phase 1 | Recruiting | Drug: ONC206 | Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma, Anaplastic Astrocytoma, Pilocytic Astrocytoma, Oligodendroglioma, Gliomatosis Cerebri, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, Ependymoma, Anaplastic, Medulloblastoma, Teratoid Rhabdoid Tumor, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Anaplastic Meningioma, Atypical Meningioma, Choroid Plexus Neoplasms, Pineal Tumor, Diffuse Astrocytoma, Glial Tumor | 102 | 2020-10-26 | Jul 2026 | — | 2025-12-18 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline GliomasNCT04617002expanded access | — | Approved for marketing | Drug: ONC201 (dordaviprone) | Glioma, H3 K27M | — | — | — | — | 2025-08-20 |
| PHIL.MI | Philogen S.p.A. | $1.1B | A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or OligodendrogliomaNCT07120984Progression-free survival (PFS) | Phase 2 | Not yet recruiting | Biological: L19TNF, L19TNF and TMZ, L19TNF and CCNU, L19TNF monotherapy, L19TNF and TMZ in recurrent astrocytoma, L19TNF and CCNU in recurrent astrocytoma, L19TNF monothery in recurrent oligodendroglioma | Glioma | 52 | 2026-01-30 | 2029-01-30 | in 894 d | 2025-08-13 |
| TCRT | Alaunos Therapeutics | $5M | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPGNCT03330197results2025-08-12The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance. | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision due to slow accrual | Biological: Ad-RTS-hIL-12 · Drug: Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG) | Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma | 6 | 2017-09-26 | 2021-09-10actual | — | 2025-08-12 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | ONC201 in Adults With Recurrent H3 K27M-mutant GliomaNCT03295396results2025-07-28Number of Patients With Overall Response | Phase 2 | Terminatedsponsor's stated reason: The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201). | Drug: Dordaviprone (ONC201) | Glioma | 73 | 2017-10-30 | 2022-12-31actual | — | 2025-07-28 |
| ACTU | Actuate Therapeutics Inc. | $25M | 9-ING-41 in Pediatric Patients With Refractory Malignancies.NCT04239092Number of participants with treatment-related adverse events as assessed by CTCAE v5 | Phase 1 | Terminatedsponsor's stated reason: The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma. | Drug: 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan | Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma | 40 | 2020-06-05 | 2025-07-07actual | — | 2025-07-17 |
| PSTV | Plus Therapeutics | $299M | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade GliomaNCT07061626Maximum Tolerated Dose (MTD) | Phase 1 | Not yet recruiting | Drug: Rhenium-186 Nanoliposome | Ependymoma, High Grade Gliomas | 56 | Sep 2025 | Mar 2027 | ≤ 223 d | 2025-07-11 |
| BIIB | Biogen | $31.4B | A Safety Study of RTA 744 in Patients With Recurrent High-Grade GliomasNCT00526812To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of RTA 744 Injection in the patient population studied and to determine the qualitative and quantitative toxic effects of RTA 744 Injection. | Phase 1 | Completed | Drug: RTA 744, RTA 744 injection | Glioma | 54 | 2005-11-30 | 2008-12-01actual | — | 2025-05-28 |
| REGN | Regeneron Pharmaceuticals | $76.1B | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent GliomaNCT03690869results2024-10-09Number of Treatment-emergent Adverse Events (TEAEs) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: cemiplimab (monotherapy), cemiplimab (maintenance) · Radiation: Conventional or hypofractionated, Re-irradiation | Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma | 57 | 2018-09-24 | 2023-05-10actual | — | 2025-04-08 |
| PSTV | Plus Therapeutics | $299M | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL TreatmentNCT05460507Assessment of safety and tolerability of a second dose of 186RNL by CED as part of standard of care >30 days following first dose. | Phase 1 | Recruiting | Drug: Retreatment Rhenium Liposome | Glioma | 40 | 2024-12-12 | 2028-03-01 | in 559 d | 2025-03-30 |
| PSTV | Plus Therapeutics | $299M | Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)NCT01906385Phase 1: Maximum Tolerated Dose | Phase 1/2 | Recruiting | Drug: Rhenium Liposome Treatment | Glioma | 55 | 2015-06-03 | Dec 2025 | — | 2025-03-26 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | ONC201 in Pediatric H3 K27M GliomasNCT03416530RP2D | Phase 1 | Terminatedsponsor's stated reason: The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201). | Drug: Dordaviprone (ONC201) | Diffuse Intrinsic Pontine Glioma, Glioma, Malignant | 134 | 2018-01-25 | 2022-12-31actual | — | 2025-02-14 |
| CADL | Candel Therapeutics, Inc. | $922M | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade GliomasNCT03576612Incidence of adverse events | Phase 1 | Completed | Biological: AdV-tk, Nivolumab · Drug: Valacyclovir, Temozolomide · Radiation · Other: Laboratory Biomarker Analysis | Glioma, Malignant | 41 | 2018-02-27 | 2023-06-30actual | — | 2025-02-14 |
| PFE | Pfizer | $155.3B | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsNCT03709680Phase 2 open-label, randomized: Event-free survival (EFS) based on Investigator assessment. | Phase 2 | Active, not recruiting | Drug: Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide | Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma | 128 | 2019-05-24 | 2024-08-26actual | — | 2025-01-14 |
| LLY | Eli Lilly and Company | $1.15T | A Dose-Escalation Study in Participants With Recurrent Malignant GliomaNCT01682187Recommended Dose for Phase 2 Studies | Phase 1 | Completed | Drug: LY2157299, Lomustine | Glioma | 66 | 2005-12-15 | 2012-05-22actual | — | 2024-11-07 |
| CADL | Candel Therapeutics, Inc. | $922M | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaNCT00589875results2024-04-03Number of Participants With Treatment Related Adverse Events | Phase 2 | Completed | Biological: CAN-2409 · Drug: Valacyclovir, Temozolomide · Radiation: Radiation therapy | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma | 52 | Mar 2007 | Dec 2015actual | — | 2024-04-03 |
| CADL | Candel Therapeutics, Inc. | $922M | A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain TumorsNCT00634231Incidence of treatment emergent adverse events | Phase 1 | Completed | Biological: AdV-tk · Drug: valacyclovir · Radiation | Malignant Glioma, Recurrent Ependymoma | 8 | Oct 2010 | Dec 2015actual | — | 2023-08-25 |
| CADL | Candel Therapeutics, Inc. | $922M | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant GliomasNCT00751270Incidence of treatment emergent adverse events | Phase 1 | Completed | Biological: AdV-tk · Drug: Valacyclovir | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma | 15 | Nov 2005 | Jan 2010actual | — | 2023-08-25 |
| NUVB | Nuvation Bio Inc. | $2.4B | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsNCT04541225Phase 1 Dose Escalation: Safety and tolerability of NUV-422 to determine the recommended Phase 2 dose (RP2D) | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: NUV-422 | Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor, Malignant Tumor of Breast, Advanced Breast Cancer, Advanced Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration-resistant Prostate Cancer, Castration Resistant Prostatic Neoplasms, Glioblastoma, Recurrent Glioblastoma | 74 | 2020-12-08 | 2022-08-31actual | — | 2023-07-14 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerNCT04730349results2023-03-24Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A | Phase 1/2 | Terminatedsponsor's stated reason: Business objectives have changed | Biological: Nivolumab, NKTR-214 | Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma | 15 | 2021-06-03 | 2022-06-22actual | — | 2023-03-24 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent GliomasNCT01986348results2021-08-026-Month Progression-Free Survival (PFS) Rate | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2 patients were in survival follow-up) | Drug: Selinexor | Glioblastoma, Glioma | 76 | 2014-03-03 | 2020-01-23actual | — | 2023-01-26 |
| 4523.T | Eisai Inc. | $8.7B | A Study in Subjects With Recurrent Malignant GliomaNCT01137604results2016-05-23Progression Free Survival (PFS) Rate at Month 6 | Phase 2 | Completed | Drug: Lenvatinib, Bevacizumab | Glioma | 151 | 2010-11-09 | 2013-03-19actual | — | 2022-09-29 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine GliomasNCT05392374expanded access | — | No longer available | Drug: ONC201 | Glioma | — | — | — | — | 2022-05-26 |
| NWBO | Northwest Biotherapeutics | $301M | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain CancerNCT00045968The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in newly diagnosed glioblastoma. | Phase 3 | Unknown status | Drug: Dendritic cell immunotherapy | Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor | 348 | Dec 2006 | Nov 2022 | — | 2022-05-18 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade GliomasNCT03134131expanded access | — | No longer available | Drug: ONC201 | Glioma | — | — | — | — | 2022-03-14 |
| BSX | Boston Scientific Corporation | $73.1B | Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme.NCT02433392Safety measured by incidence of adverse events as assessed by CTCAE v4.0 | Phase 1 | Terminatedsponsor's stated reason: The decision to terminate the trial was based on the slow rate of recruitment across the programme of studies | Procedure: CM-BC2 | Glioma | 9 | Dec 2011 | Jul 2015actual | — | 2021-04-21 |
| BSX | Boston Scientific Corporation | $73.1B | Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade GliomaNCT02481960Safety measured by incidence of adverse events as assessed by CTCAE v4 | Phase 1/2 | Terminatedsponsor's stated reason: The decision to terminate the trial was based on the slow rate of recruitment across the programme of studies\] | Procedure: CM-BC2 Irinotecan drug-eluting bead | Glioma | 5 | 2012-02-21 | 2015-12-18actual | — | 2021-04-21 |
| PII | Polaris Group | $3.8B | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and CisplatinNCT02029690Define initial estimates of efficacy, measured by RECIST 1.1 criteria for non-squamous NSCLC, advanced peritoneal mesothelioma, metastatic uveal melanoma, HCC, glioma and sarcomatoid cancers for ADI-PEG 20 in combination with pemetrexed and cisplatin. | Phase 1 | Terminated | Drug: ADI-PEG 20 | Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma, Hepatocellular Carcinoma, Glioma, Sarcomatoid Carcinoma | 85 | 2014-04-23 | 2018-08-15actual | — | 2020-09-25 |
| ABBV | AbbVie | $457.5B | Study Evaluating ABT-414 in Japanese Subjects With Malignant GliomaNCT02590263Percentage of participants with adverse events | Phase 1/2 | Completed | Radiation: Whole Brain Radiation · Drug: Temozolomide, ABT-414 | Malignant Glioma, Glioblastoma Multiforme | 53 | 2015-08-24 | 2020-08-27actual | — | 2020-09-03 |
| PFE | Pfizer | $155.3B | First in Patient Study for PF-06840003 in Malignant GliomasNCT02764151results2020-01-27Number of Participants With Dose Limiting Toxicities (DLTs) [Part 1] | Phase 1 | Terminatedsponsor's stated reason: Sponsor decided to prematurely terminate the study and not to pursue marketing approval for the indication of malignant glioma. | Drug: PF-06840003 | Oligodendroglioma, Astrocytoma, Malignant Glioma | 17 | 2016-09-09 | 2018-12-26actual | — | 2020-01-27 |
| 4523.T | Eisai Co., Ltd. | $8.7B | Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade GliomaNCT02300506observationalSurvival rate | — | Completed | Other: No intervention | Malignant Glioma | 507 | 2014-01-10 | 2016-07-10actual | — | 2018-11-05 |
| CLDX | Celldex Therapeutics | $3.3B | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma MultiformeNCT00458601Progression-free survival status | Phase 2 | Completed | Drug: CDX-110 with GM-CSF, Temozolomide | Malignant Glioma | 82 | Aug 2007 | Nov 2010actual | — | 2018-01-16 |
| 4523.T | Eisai Co., Ltd. | $8.7B | Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)NCT02300532observationalNumber of Adverse Events/Serious Adverse Events | — | Completed | Other: No intervention | Malignant Glioma | 561 | 2013-01-10 | 2014-07-10actual | — | 2017-02-27 |
| LLY | Eli Lilly and Company | $1.15T | A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant GliomaNCT01220271Phase 1: Recommended dose for Phase 2 portion | Phase 1/2 | Completed | Drug: LY2157299, Radiation, Temozolomide | Glioma | 75 | Apr 2011 | Aug 2015actual | — | 2017-02-16 |
| AMGN | Amgen | $229.9B | AMG 595 First-in-Human in Recurrent GliomasNCT01475006Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs | Phase 1 | Completed | Drug: AMG 595 | Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme | 32 | Feb 2012 | Apr 2016actual | — | 2016-04-15 |
| AMGN | Amgen | $229.9B | A Phase II Study to Treat Advanced Malignant GliomaNCT00427440Assess best objective confirmed response rate in subjects with advanced malignant glioma receiving AMG 102 treatment | Phase 2 | Completed | Drug: AMG 102 at 20 mg/kg, AMG 102 at 10 mg/kg | Advanced Malignant Glioma | 61 | Nov 2006 | Dec 2008actual | — | 2015-04-27 |
| ONCY | Oncolytics Biotech | $108M | Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant GliomasNCT00528684determine the maximum tolerated dose | Phase 1 | Completed | Biological: REOLYSIN® | Malignant Glioma | 18 | Jul 2006 | Apr 2010actual | — | 2014-10-02 |
| GEHC | GE Healthcare | $33.0B | A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and AngiogenesisNCT00565721results2014-08-08Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 (Beta-3 Integrin) Integrin Expression in Tumors. (Correlation Between Ki_inp-Patlak and αvβ3 Optical Density) | Phase 2 | Completed | Drug: Fluciclatide Injection - (AH111585 (F18)) | High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma, Melanoma | 33 | Nov 2007 | Oct 2011actual | — | 2014-08-18 |
| GEHC | GE Healthcare | $33.0B | Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) InjectionNCT00918281results2014-06-09Test Image and Retest Image Reproducibility of Fluciclatide Injection ([18F]AH111585) Uptake by Solid Tumors Following Intravenous Administration of AH111585 (18F) Injection Via PET Imaging. | Phase 2 | Completed | Drug: Fluciclatide Injection | Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer, Sarcoma, Renal Cell Carcinoma, Breast Cancer | 70 | Jun 2009 | Sep 2011actual | — | 2014-06-09 |
| CLRB | Cellectar Biosciences, Inc. | $24M | Open-Label Study of I-131-CLR1404 in Subjects With Recurrent GliomaNCT01778088Evaluate the 6-month survival rate of subjects receiving I-131-CLR1404 for relapsed glioma | Phase 2 | Withdrawn | Drug: I-131-CLR1404 Injection | Glioma | 0 | May 2014 | Jun 2014 | — | 2014-02-25 |
| PFE | Pfizer | $155.3B | Combination of Irinotecan and Temozolomide in Children With Brain Tumors.NCT00404495results2012-02-17Percentage of Participants With Objective Response of Complete Response or Partial Response | Phase 2 | Completed | Drug: Irinotecan, Temozolomide | Glioma, Medulloblastoma | 83 | Apr 2007 | Jan 2011actual | — | 2012-04-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY317615 in Patients With Brain TumorsNCT00190723To establish data regarding the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas. | Phase 2 | Completed | Drug: Enzastaurin | Malignant Glioma | 120 | Oct 2002 | — | — | 2007-01-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Glioma is matched — 11 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Glioma
- Malignant Glioma
- Diffuse Intrinsic Pontine Glioma
- Oligodendroglioma
- High Grade Glioma
- Glioma, Malignant
- Diffuse Midline Glioma, H3 K27M-Mutant
- Advanced Malignant Glioma
- High Grade Gliomas
- High-grade Glioma
- IDH1-mutant Glioma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Glioma” (a text search, wider than this page)